

Review of the Paediatric and Orphan Regulation


4th Nordic Conference on Paediatric Medicines13 September 2022

Fabio D'Atri

DG SANTE

57 years of EU pharmaceuticals regulation SAFETY – EFFICACY - QUALITY

Thalidomide disaster exemplifies the need for EVIDENCE-BASED AUTHORISATION



Responsibilities shared between EU and Member States



- Centralised authorisation procedure
- Inspections of manufacturing sites
- Pharmacovigiliance

EMA and network of National Competent Authorities



By EU-level standards


- Decentralised procedure and mutual recognition procedure to authorise medicines in MS
- Organisation and delivery of health services and medical care
- P&R for medicinal products or their inclusion in the scope of national health insurance schemes

Strictly MS competence!



•

PHARMACEUTICAL STRATEGY FOR EUROPE





Learning from COVID-19, towards a crisisresistant system Ensuring accessibility and affordability of medicines



Supporting sustainable innovation, emerging science and digitalisation



Reducing medicines shortages and securing strategic autonomy

#EUPharmaStrategy



European Commission

Revising the pharmaceutical legislation

A comprehensive review of the pharmaceutical legislation is ongoing:

- Simplification and streamlining of approval procedures and flexibility for timely adaptation
- Adapt legislation to cutting-edge products, scientific developments and transformations
- Take forward the use of high performance computing and AI
- Ensure environmental sustainability of manufacturing and use of pharmaceuticals



- Promote innovation in particular in areas of UMN;
- Balanced system of incentives rewarding innovation and promote affordability and sustainability of health systems;
- Increase access to medicines for EU patients;
- (Reduce environmental footprint);
- Reduce regulatory burden.



- Promote innovation in particular in areas of UMN;
- Balanced system of incentives rewarding innovation and promote affordability and sustainability of health systems;
- Increase access to medicines for EU patients;
- (Reduce environmental footprint);
- Reduce regulatory burden.



- Promote innovation in particular in areas of UMN;
- Balanced system of incentives rewarding innovation and promote affordability and sustainability of health systems;
- Increase access to medicines for EU patients;
- (Reduce environmental footprint);
- Reduce regulatory burden.



- Promote innovation in particular in areas of UMN;
- Balanced system of incentives rewarding innovation and promote affordability and sustainability of health systems;
- Increase access to medicines for EU patients;
- (Reduce environmental footprint);
- Reduce regulatory burden.



- Promote innovation in particular in areas of UMN;
- Balanced system of incentives rewarding innovation and promote affordability and sustainability of health systems;
- Increase access to medicines for EU patients;
- (Reduce environmental footprint);
- Reduce regulatory burden.



Thank you



© European Union 2020

Unless otherwise noted the reuse of this presentation is authorised under the <u>CC BY 4.0</u> license. For any use or reproduction of elements that are not owned by the EU, permission may need to be sought directly from the respective right holders.



Slide xx: element concerned, source: e.g. Fotolia.com; Slide xx: element concerned, source: e.g. iStock.com